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COMMENTARY
Report from the 5th cardiovascular outcome 
trial (CVOT) summit
Oliver Schnell1*, Eberhard Standl1, Xavier Cos2, Hiddo JL Heerspink3,4, Baruch Itzhak5, Nebojsa Lalic6, 
Michael Nauck7 and Antonio Ceriello8
Abstract 
The 5th Cardiovascular Outcome Trial (CVOT) Summit was held in Munich on October 24th–25th, 2019. As in previ-
ous years, this summit served as a reference meeting for in-depth discussions on the topic of recently completed and 
presented CVOTs. This year, focus was placed on the CVOTs CAROLINA, CREDENCE, DAPA-HF, REWIND, and PIONEER-6. 
Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabe-
tologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussions evolved from CVOTs to 
additional therapy options for heart failure (ARNI), knowledge gained for the treatment and prevention of heart failure 
and diabetic kidney disease in populations with and without diabetes, particularly using SGLT-2 inhibitors and GLP-1 
receptor agonists. Furthermore, the ever increasing impact of CVOTs and substances tested for primary prevention 
and primary care was discussed. The 6th Cardiovascular Outcome Trial Summit will be held in Munich on October 
29th–30th, 2020 (https ://www.cvot.org).
Keywords: Cardiovascular risk, Diabetes, CVOT, CAROLINA, CREDENCE, DAPA-HF, REWIND, PIONEER-6, SGLT-2 
inhibitor, GLP-1 receptor agonist
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Background
Diabetes mellitus (DM) presents an ever increasing bur-
den of our time. Within the next 25  years, the Interna-
tional Diabetes Federation (IDF) estimates an escalation 
of patient numbers starting at a 15% increase of persons 
with DM in Europe, over a 33% increase in North Amer-
ica and the Caribbean to a 74%, 96%, and even a 143% 
increase in South-East Asia, the Middle-East and North 
Africa, and Africa, respectively [1]. Cardiovascular dis-
ease (CVD) such as, but not limited to, stroke, myocar-
dial infarction (MI), atherosclerosis, heart failure (HF), 
coronary heart disease (CHD), angina pectoris, and car-
diovascular (CV) death present major comorbidities of 
DM. A recent systemic literature analysis with evidence 
on over 4.5 million persons with type 2 diabetes mellitus 
(T2DM) across the globe revealed a prevalence of ≈ 32% 
CVD, ≈ 29% atherosclerosis, ≈ 21% CHD, ≈ 15 HF, ≈ 10% 
MI, and ≈ 7.5% stroke [2]. Consequently, CVD-related 
deaths represented 50.3% of all T2DM-related deaths 
[2]. Similarly, it has been proposed that at least 50% of 
all persons with T2DM worldwide have diabetic kid-
ney disease (DKD) [3]. It has been shown that patients 
with chronic kidney disease (CKD) have an ≈ 18–47% 
increased mortality, depending on development of albu-
minuria and/or decline of glomerular filtration rate 
(GFR) [4]. In summary, this mandates affordable, acces-
sible, but most importantly effective and save means of 
glycaemic control.
As some glucose-lowering medications raised concerns 
of elevated micro- and macrovascular risk, the American 
Food and Drug Administration (FDA) mandated Cardio-
vascular Outcome Trials (CVOTs) in diabetes in 2008, 
to prevent an undesired increase of CV risk [5]. Thus, 
approved glucose-lowering substances have undergone 
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usually investigating a combined primary endpoint of 
CV death, non-fatal stroke, non-fatal MI (3-point major 
adverse cardiovascular event; 3P-MACE) and several 
pre-specified CV and/or renal secondary endpoints. So 
far, most CVOTs in diabetes were conducted for 3 sub-
stance classes emerging in the last 2 decades: dipeptidyl 
peptidase 4 inhibitors (DPP-4is; alogliptin [6], linagliptin 
[7], saxagliptin [8], and sitagliptin [9]), sodium/glucose 
co-transporter 2 inhibitors (SGLT-2is; canagliflozin [10], 
dapagliflozin [11], empagliflozin [12]), and glucagon-like 
1 receptor agonists (GLP-1 RAs; albiglutide [13], exena-
tide [14], liraglutide [15], lixisenatide [16], and semaglu-
tide [17]).
In 2019, the list of CVOTs in diabetes was expanded 
by 3 CVOTs (CAROLINA [18]—linagliptin; REWIND 
[19]—dulaglutide; PIONEER-6 [20]—oral semaglutide), 
a renal outcome trial (CREDENCE [21]—canagliflozin), 
and a HF outcome trial in patients with HF and reduced 
ejection fraction (HFrEF) with and without diagnosed 
DM (DAPA-HF [22]—dapagliflozin). Also, a renal trial on 
an endothelin A receptor antagonist (SONAR [23]—atra-
sentan) was published. In addition, a trial on angioten-
sin-neprilysin inhibition in HF with preserved ejection 
fraction (HFpEF; PARAGON-HF [24]—sacubitril-val-
sartan) was published. As in previous years [25–28], we 
present and summarise key aspects discussed at the 5th 
CVOT Summit in October 2019. The 5th CVOT Summit 
was an interdisciplinary platform and was held in con-
junction with four study groups of the European Asso-
ciation for the Study of Diabetes (EASD): the Diabetes 
and Cardiovascular Disease EASD Study Group (DCVD, 
www.dcvd.org), Primary Care Diabetes Europe (PCDE, 
www.pcdeu rope.org), European Diabetic Nephropathy 
Study Group (EDNSG, www.ednsg .org), and the Incretin 
study group. Participants from 4 continents with speciali-
ties in endocrinology & diabetology, cardiology, nephrol-
ogy, and primary care contributed to the discussions of 
the 5th CVOT Summit in 2019 (www.cvot.org).
Updates on CVOTs
A summary of characteristics and results of renal, HF and 
CV outcome trials published in 2019 is listed in Tables 1, 
2, 3, and 4.   
DDP‑4 inhibitors
The previously published CARMELINA trial [7] investi-
gated CV effects of linagliptin compared to placebo (pri-
mary endpoint 3P-MACE, HR 1.02 [95% CI 0.89–1.17]) 
in patients with T2DM at high risk of CV and kidney 
events. The recently published CAROLINA trial [18] 
assessed CV outcomes of linagliptin compared to a sul-
fonylurea (glimepiride). Included patients were adults 
with T2DM, HbA1c of 6.5–8.5%, and high CV risk (1. 
established atherosclerotic CVD (ASCVD), 2.  ≥ 2 risk 
factors, 3. age ≥ 70  years, 4. evidence of microvascular 
complications). HbA1c of eligible participants currently 
receiving sulfonylurea or glinide as monotherapy or in 
combination with metformin or α-glucosidase inhibitors 
was restricted from 6.5 to 7.5% and sulfonylurea/glinide 
therapy was discontinued at randomization. The primary 
outcome of the CAROLINA trial was 3P-MACE, with an 
additional key secondary CV endpoint (4P-MACE) and 
two key secondary glycaemic endpoints (1. treatment 
and maintenance of HbA1c ≤ 7.0% at final visit without 
the need for rescue medication, without any moderate/
severe hypoglycaemic episodes, and without > 2% weight 
gain; 2. treatment and maintenance of HbA1c ≤ 7.0% at 
final visit without the need for rescue medication and 
without > 2% weight gain) [18].
The primary endpoint was not significantly changed 
(HR 0.98 [95% CI 0.84–1.14]; p < 0.001 for non-inferior-
ity; p = 0.76 for superiority), however, linagliptin dem-
onstrated non-inferiority compared to glimepiride. As 
superiority was not observed, key secondary and other 
secondary/tertiary endpoints were presented descrip-
tively only. Overall, linagliptin demonstrated CV safety, 
yet no CV benefit compared to glimepiride, also reflected 
in the endpoint of any adjudicated-confirmed CV event 
(HR 0.96 [95% CI 0.85–1.09]) [18]. However, on the other 
hand and equally important, it has been proposed subse-
quently that this trial not only demonstrated CV safety of 
linagliptin, but also provided reliable evidence for the CV 
safety of glimepiride [18, 29].
SGLT‑2 inhibitors
The CREDENCE trial [21] assessed the renal and CV out-
comes in 4401 patients with T2DM and albuminuric CKD 
over a median follow-up of 2.62  years. Eligible patients 
were ≥ 30  years, had T2DM with a HbA1c of 6.5–12%, 
and CKD defined as eGFR ≥ 30 to < 90  ml/min/1.73  m2, 
and an urine albumin-creatinine ratio (UACR) of > 300 
to < 5000 mg/g. In addition, all patients were required to 
be on a stable dose of angiotensin-converting-enzyme 
(ACE) inhibitor 1  month prior to randomization (dual-
agent treatment with ACE, angiotensin-receptor blocker 
(ARB) or mineralocorticoid receptor antagonist (MRA) 
was not permitted). The primary composite outcome was 
end-stage kidney disease (ESKD), doubling of serum-
creatinine level from baseline, or death from renal or CV 
cause. Pre-specified secondary outcomes (in hierarchical 
testing order) encompassed (a) a composite of CV death 
or hospitalization for HF (HHF), (b) a composite of CV 
death, MI, or stroke, (c) HHF, (d) a composite of ESKD, 
doubling of serum-creatinine level, or renal death, (e) CV 
death, (f ) all-cause mortality, and (g) a composite of CV 
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death, MI, stroke, HHF or hospitalization for unstable 
angina.
Administration of canagliflozin resulted in a 30% lower 
relative risk (HR 0.70 [95% CI 0.59–0.82]; p < 0.00001) of 
the primary composite outcome, compared to placebo. 
Effects were consistent for other renal outcomes (approx-
imately 28–34% risk reduction) like ESKD, doubling of 
serum-creatinine, or renal death as well as across individ-
ual renal components of composite outcomes, including 
the doubling of serum-creatinine level and the explora-
tory outcome (dialysis, kidney transplantation, or renal 
death) [21]. Similarly, CV outcomes such as CV death, 
the composite of CV death or HHF, the composite of CV 
death, MI, or stroke, and the secondary outcome HHF 
were reduced by 20% to approximately 40% [21].
In terms of adverse events of special interest, there 
was no significant increase in lower limb amputation 
rate in the canagliflozin group compared to the con-
trol group (HR 1.11 [95% CI 0.79–1.56]). Previously 
published data of the CANVAS-Program had shown 
a small increase in atraumatic lower extremity ampu-
tations [30]. Rates of diabetic ketoacidosis were over-
all low (11 events for 2200 patients in the canagliflozin 
group, 1 event for 2197 patients in the control group), 
yet higher compared to placebo (HR 10.80 [95% CI 
1.39–83.65]) [21].
The DAPA-HF study [22] investigated effects of dapa-
gliflozin (10 mg daily) in 4744 patients with HFrEF over 
a median follow-up time of 1.52  years. Included were 
patients with diagnosed DM (41.8%) and without diag-
nosed DM (58.2%). Inclusion criteria encompassed an 
ejection fraction of ≤ 40% and New York Heart Associa-
tion (NYHA) class II, III, or IV symptoms. In addition, 
participants were required to receive standard HF device-
and drug therapy, participants with T2DM were able to 
continue their glucose-lowering medication, yet to be 
adjusted as required. Concomitant therapy with MRAs 
was encouraged. Primary outcome was a composite of 
Table 1 Overview of basic characteristics of renal, heart failure and cardiovascular outcome studies completed in 2019
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worsening HF or death from CV causes. Key secondary 
outcomes included HHF or CV death [22].
Dapagliflozin showed significant improvement of the 
primary outcome (HR 0.74 [95% CI 0.65–0.85]; p < 0.001), 
with similar risk reductions detected for HHF (HR 0.70 
[95% CI 0.59–0.83]) and CV death (HR 0.82 [95% CI 
0.69–0.98]). Significant improvement of secondary out-
comes was observed as well: risk for CV death or HHF 
(HR 0.75 [95% CI 0.65–0.85]; p < 0.001] and total number 
of HHF and CV deaths [HR 0.75 [95% CI 0.65–0.88]; 
p < 0.001) were significantly reduced. In addition, the 
increase in the Kansas City Cardiomyopathy Ques-
tionnaire Score (KCCQ; higher scores indicating fewer 
symptoms) was significant in the dapagliflozin group, 
compared to the placebo group (HR 1.18 [95% CI 1.11–
1.26]; p < 0.001) [22]. Analysis of pre-specified subgroups 
revealed that patients with NYHA class II symptoms 
had the greatest risk reduction of the primary composite 
Table 2 CVOTs completed in 2019: comparison of results
a After accounting for α = 0.009 spent on the primary outcome for the interim analysis, the α for the final analysis is 0.0467 [HR 0.88 (95.33% CI 0.79–0.99)]
b Death from cardiovascular causes
c Death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, unstable angina resulting in hospitalization, or heart failure resulting in 
hospitalization
d CV death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for unstable angina pectoris
e Requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions
Cardiovascular 
endpoints
CAROLINA [18] PIONEER‑6 [20] REWIND [19]
Class HR (95% CI)
p‑value
Class HR (95% CI)
p‑value
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outcome as a result of dapagliflozin treatment. Further-
more, subgroup analysis demonstrated that patients with 
and without diagnosed T2DM had near to equal risk 
reductions (with T2DM HR 0.75 [95% CI 0.63–0.90]; 
without T2DM HR 0.73 [95% CI 0.60–0.88]). Similarly, 
no discrimination of risk reduction of the primary out-
come could be observed according to the eGFR-value 
(< or ≥ 60 ml/min/1.73 m2) or MRA treatment at baseline 
[22].
No significant increase of adverse events of interest was 
observed for the dapagliflozin group compared to the 
placebo group. This encompassed comparable rates of 
volume depletion, renal adverse events, fractures, ampu-
tation, and major hypoglycaemia or diabetic ketoacidosis 
(the latter in patients with T2DM only) [22].
GLP‑1 receptor agonists
The REWIND trial [19] analysed CV effects of once-
weekly administration of 1.5  mg dulaglutide in 9901 
patients. Inclusion criteria comprised: (1) age ≥ 50 years 
with established T2DM (HbA1c ≤ 9.5% without lower 
limit, on stable doses of ≤ 2 oral glucose-lowering drugs 
with or without basal insulin if BMI ≥ 23  kg/m2) and 
with vascular disease; (2) age ≥ 55 years with established 
T2DM and vascular disease or subclinical vascular dis-
ease; (3) age ≥ 60 years with established T2DM and vas-
cular disease or subclinical vascular disease or ≥ 2 CV 
risk factors [19]. The primary composite outcome was a 
composite of non-fatal MI, non-fatal stroke, and death 
from CV- or unknown causes. In addition, several sec-
ondary outcomes were analysed, comprising a composite 
clinical microvascular outcome which included diabetic 
retinopathy or renal disease.
Dulaglutide met its primary endpoint (HR 0.88 [95% 
CI 0.79–0.99); p = 0.026), thus significantly decreased 
3P-MACE events over placebo. The pre-specified com-
posite clinical microvascular outcome was significantly 
reduced in the active treatment group (HR 0.87 [95% 
CI 0.79–0.95]; p = 0.0020]) [19]. There were no signifi-
cant differences in the subgroup analysis for the primary 
outcome with respect to age, sex, duration of diabetes, 
history of CVD, baseline HbA1c, and BMI when compar-
ing dulaglutide to placebo [19]. An exploratory analysis 
Table 3 Renal outcome trials completed in 2019: comparison of results vs. placebo
a Acute kidney injury
CREDENCE [21]
Class and cardiovascular/renal endpoints HR (95% CI) p‑value Event Event rate (%) active vs. 
placebo group
Primary composite endpoint Primary composite outcome 11.1 vs. 15.5
 End-stage kidney disease, sustained doubling of serum 
creatinine level, death from renal or CV disease
0.70 (0.59–0.82) p = 0.00001
Secondary outcome Adverse events Event rate (%) active vs. 
placebo group (p-value)
 CV death or hospitalization for heart failure 0.69 (0.57–0.83) p < 0.001 Renal event 3.9 vs. 4.5a (–)
Secondary outcome Acute pancreatitis 0.2 vs. < 0.1 (–)
 CV death, myocardial infarction, or stroke 0.80 (0.67–0.95) p = 0.01 Diabetic ketoacidosis 0.5 vs. < 0.1 (–)
Secondary outcome
 Hospitalization for heart failure 0.61 (0.47–0.80) p < 0.001
Secondary outcome
 End-stage kidney disease, doubling of serum creati-
nine level, or renal death
0.66 (0.53–0.81) p < 0.001
Secondary outcome
 All-cause death 0.83 (0.68–1.02)
Secondary outcome
 CV death, myocardial infarction, stroke, or hospitaliza-
tion for heart failure or for unstable angina
0.74 (0.63–0.86)
Secondary outcome
 Dialysis, kidney transplantation, or renal death 0.72 (0.54–0.97)
Exploratory outcome
 Cardiovascular death 0.78 (0.61–1.00) p = 0.05
Exploratory outcome
 Renal death 0.78 (0.61–1.00)
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of a composite renal outcome (new macroalbuminuria, 
sustained decline in eGFR of ≥ 30%, and chronic renal 
replacement therapy) demonstrated that dulaglutide 
significantly reduced the composite renal outcome (HR 
0.85 [95% CI 0.77–0.93]), which remained significant 
if the sustained decline in eGFR was redefined to ≥ 40% 
and ≥ 50% [31].
The PIONEER-6 trial [20] investigated CV safety of 
oral semaglutide, the first FDA-approved oral GLP-1 RA 
[32]. PIONEER-6 included a total of 3183 patients ran-
domized to receive oral semaglutide (14  mg daily after 
an 8 week run-in period of 3 mg and 7 mg oral semaglu-
tide for 4  weeks, respectively) or placebo for a median 
follow-up period of 15.9  months. Eligible patients had 
an age ≥ 50  years and established CVD or CKD, or, 
if ≥ 60  years of age ≥ 1 CV risk factor. In total, 84.7% of 
patients were ≥ 50  years and had established CVD of 
CKD [20]. Primary outcome was a composite of death 
from CV causes (including undetermined causes of 
death), non-fatal MI, or non-fatal stroke. Secondary CV 
outcomes encompassed (a) an expanded composite out-
come (primary endpoint plus unstable angina resulting 
in hospitalization or HF resulting in hospitalization), (b) 
a composite of death from any cause, non-fatal MI, or 
non-fatal stroke and (c) the individual components of the 
previously listed outcomes. Efficacy outcomes included 
HbA1c level, body weight, and lipid levels [20].
In patients receiving oral semaglutide the primary 
outcome was met, affirming non-inferiority of oral 
semaglutide (HR 0.79 [95% CI 0.57–1.11]; p < 0.001), yet 
not demonstrating superiority over placebo (p = 0.17) if 
added to standard of care [20]. Similarly, the expanded 
composite outcome (HR 0.82 [95% CI 0.61–1.10), the 
composite outcome made up of death from any cause, 
non-fatal MI, or non-fatal stroke (HR 0.77 [95% CI 0.56–
1.05]), and the individual components of the latter two 
showed reductions in the oral semaglutide treatment arm 
(albeit not significant and to be considered exploratory 
due to non-significance of the superiority analysis of the 
primary outcome and hierarchical testing design) [20]. 
Exceptions were non-fatal MI and unstable angina result-
ing in hospitalization with a HR 1.18 [95% CI 0.73–1.90] 
and 1.56 [95% CI 0.60–4.01], respectively [20]. Analy-
sis of efficacy outcomes demonstrated a reduction of 
HbA1c (− 0.7% difference between groups), body weight 
(− 3.4  kg difference between groups), and a modest 
decrease of LDL-cholesterol and triglycerides in favour of 
oral semaglutide over placebo [20].
Angiotensin‑receptor‑neprilysin‑inhibitors (ARNI)
In the previously published PARADIGM-HF [33] trial, 
a significant reduction of HFrEF was demonstrated for 
sacubitril-valsartan, compared to enalapril. The 2019 
published PARAGON-HF trial [24] investigated the 
effects of sacubitril-valsartan compared to valsartan 
in patients with HFpEF. Eligible patients were 50  years 
or older, had signs and symptoms of HF (NYHA class 
II–IV), an ejection fraction of ≥ 45%, had evidence of 
Table 4 Heart failure outcome trials completed in 2019: comparison of results vs. placebo
a All cases of diabetic ketoacidosis occurred in patients with diabetes at baseline
DAPA‑HF [22]
Class and cardiovascular/renal endpoints HR (95% CI)
p‑value
Event Event rate (%) active vs. 
placebo group
Primary composite endpoint Primary composite outcome 16.3 vs. 21.2
 Worsening heart failure or death from CV causes 0.74 (0.65–0.85) p < 0.01
Secondary outcome Adverse events No. (%) active vs. placebo 
group (p-value)
 CV death or heart-failure hospitalization 0.75 (0.65–0.85) p < 0.001 Renal event 6.5 vs.7.2 (0.36)
Secondary outcome Acute pancreatitis – (–)
 Total no. of hospitalizations for heart failure and 
CV deaths
0.75 (0.65–0.88) p < 0.001 Diabetic ketoacidosis 0.1 vs.  0a (–)
Secondary outcome
 Change in KCCQ total symptom score at 
8 months
1.18 (1.11–1.26) p < 0.001
Secondary outcome
 Worsening renal function 0.71 (0.44–1.16)
Secondary outcome
 All-cause death 0.83 (0.71–0.97)
Exploratory outcome
 Cardiovascular death 0.82 (0.69–0.98)
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structural heart disease, and diuretic therapy [24]. 43.5% 
of participants in the sacubitril-valsartan group had dia-
betes. The primary composite outcome was HHF and 
death from CV causes. Secondary outcomes encom-
passed change from baseline to 8 months in the clinical 
summary score on the KCCQ, change from baseline to 
8 months in NYHA class, first occurrence of a decline in 
renal function, and death of any cause [24].
Sacubitril-valsartan did not meet the predeter-
mined level of statistical significance (rate ratio (RR) 
0.87 [95% CI 0.75–01.01]; p = 0.06), thus all other out-
comes were considered exploratory. In general, positive 
effects of sacubitril-valsartan, compared to valsartan, 
were observed. These included a decreased rate of HHF 
(RR 0.85 [95% CI 0.72–1.00]), a higher percentage of 
patients with an improvement of 5 or more points in 
the KCCQ clinical summary score (odds ratio (OR) 1.30 
[95% CI 1.04–1.61]), and a higher percentage of patients 
with an improvement of NYHA class (OR 1.45 [95% 
CI 1.13–1.86]). Renal composite outcome (death from 
renal failure, ESRD, or ≥ 50% eGFR decline) was reduced 
by 50% (HR 0.50 [95% CI  0.33–0.77]). No difference 
in death from any cause was observed (HR 0.97 [95% 
CI 0.84–1.13]). Subgroup analysis revealed a stronger 
effect of sacubitril-valsartan, compared to valsartan, in 
females vs. males, a left-ventricular ejection fraction of 
median ≤ 57% vs. > 57%, and MRA use vs. no MRA use, 
respectively. No differences were observed according to 
DM status [24].
Compared to valsartan, significant improvements 
of adverse events of special interest were observed: 
sacubitril-valsartan caused significantly less events of 
hypotension (systolic blood pressure < 100  mmHg), less 
events of elevated serum creatinine levels (≥ 2.0, ≥ 2.5, 
and ≥ 3.0  mg/dl, respectively), less events of elevated 
serum potassium levels (> 5.5 and > 6.0 mmol/l), and less 
angioedema events [24].
Endothelin A receptor antagonists
The endothelin A receptor antagonist atrasentan has its 
history in the field of oncology, however, more recent 
clinical trials like the SONAR trial [23] have begun 
to investigate atrasentan in the context of renal dis-
ease. The SONAR trial differed from conventional out-
come trials by using an enrichment design according to 
responsiveness to treatment (≥ 30% UACR reduction 
without substantial fluid retention) to investigate drug 
effects in the population with the highest expected ben-
efit (responders), whilst aiming to minimize previously 
anticipated complications (risk of HF due to fluid reten-
tion). To assess effects in non-responders, a subgroup of 
non-responders (< 30% UACR without substantial fluid 
retention) was included [23]. Atrasentan significantly 
reduced the primary outcome (HR 0.65 [95% CI 0.49–
0.88]; p = 0.0047), subdivided into a significant reduc-
tion of doubling of serum-creatinine (HR 0.61 [95% CI 
0.43–0.87]; p = 0.0055) and a non-significant reduc-
tion of ESKD (HR 0.73 [95% CI 0.53–1.01]; p = 0.060) 
[23]. In non-responders, the primary renal outcome was 
not significantly reduced (HR 0.75 [95% CI 0.55–1.03]; 
p = 0.079). The authors concluded that using an enrich-
ment strategy, designed to select patients most likely 
to benefit from a treatment may become a trendsetting 
option for future trials, in accordance with the concept of 
personalized medicine [23].
Key topics discussed during the 5th CVOT Summit
SGLT‑2i and GLP1‑RA: a focus on heart and kidney
Including the CVOTs published in 2019, currently 7 
CVOTs with GLP-1 RAs [13–17, 19, 20] and 5 CVOTs 
with SGLT-2is [10–12, 21, 22] have been published and 
their evidence analysed by multiple recent meta-analyses 
[34–38]. While it is clear that meta-analyses have to be 
considered with care, particularly with regard to vary-
ing inclusion criteria and pre-specified outcomes of the 
underlying studies, all recent meta-analyses convey the 
clear message that both GLP-1 RAs and SGLT-2is con-
sistently show cardiovascular and renal benefits [34–38], 
yet with slightly different benefits, as displayed in cur-
rently recommended treatment algorithms and guide-
lines [39, 40].
A meta-analysis encompassing the trials EMPA-REG 
Outcome [12], CANVAS Program [10], and DECLARE-
TIMI 58 [11] compared CV effects of SGLT-2is [36]. 
Overall, SGLT-2is in these trials reduced the risk of 
3P-MACE significantly (HR 0.89 [95% CI 0.83–0.96]; 
p = 0.0014), with overall significant reduction of MI (HR 
0.89 [95% CI 0.80–0.98]; p = 0.0177) and CV death (HR 
0.84 [95% CI 0.75–0.94]; p = 0.0023), yet without a signif-
icant effect on stroke (HR 0.97 [95% CI 0.86–1.10]) [36]. 
In contrast to GLP-1 RAs, SGLT-2is markedly reduced 
the risk for the composite of CV death or HHF (HR 0.77 
[95% CI 0.71–0.84]; p < 0.0001), and HHF (HR 0.69 [0.61–
0.79]; p < 0.0001) [36]. In both meta-analyses, effects of 
treatment (GLP-1 RA or SGLT-2i) were driven by the 
patient groups with prior CVD, whereas in either case no 
significant risk reduction was observed for patients with 
multiple risk factors [34, 36].
A follow up meta-analyses by Neuen et al. [38] inves-
tigated the overall renal effects observed in the SGLT-2i 
outcome trials CREDENCE [21], DECLARE-TIMI 58 
[11], the CANVAS Program [10], and EMPA-REG OUT-
COME [12]. Even though a high number of patients was 
included in the latter three CVOTs, most participants 
were at low risk of clinically relevant kidney outcomes. 
With the publication and inclusion of CREDENCE, a trial 
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primarily powered for renal outcomes in patients with 
established DKD [21], the number of patients with renal 
disease increased substantially, allowing for a better pow-
ered meta-analysis [38]. They showed significant overall 
risk reduction of dialysis, transplantation, or death due to 
kidney disease (HR 0.67 [95% CI 0.52–0.86]; p = 0.0019), 
ESKD (HR 0.65 [95% CI 0.53–0.81]; p < 0.0001), and sub-
stantial loss of kidney function, ESKD, or death due to 
kidney disease (HR 0.58 [95% CI 0.51–0.66]; p < 0.0001) 
[38]. Similarly, an overall significantly reduced risk 
of acute kidney injury (HR 0.75 [95% CI 0.66–0.85]; 
p < 0.0001) was demonstrated. A stratification of the 
combined outcome of substantial loss of kidney func-
tion, ESKD, or death due to kidney disease by baseline 
eGFR, UACR and use of RAS blockade demonstrated 
that overall, significant risk reduction was observed to be 
independent from eGFR (eGFR of < 45, 45– < 60, 60– < 90, 
or ≥ 90  ml/min/1.73  m2) and UACR (UACR of > 30, 
30–300, or > 300  mg/g), yet with comparably better risk 
reduction upon concomitant RAS blockade [38].
One of the most recent meta-analyses, by Kristensen 
et  al. [34], including all 7 GLP-1 RA CVOTs, demon-
strated that treatment with GLP-1 RA resulted in a sig-
nificant overall risk reduction of the CV endpoints of 
3P-MACE (HR 0.88 [95% CI 0.82–0.94]; p < 0.0001), 
and its components CV death (HR 0.88 [95% CI 0.81–
0.96]; p = 0.003), fatal or non-fatal MI (HR 0.91 [95% CI 
0.84–1.00]; p = 0.043), and fatal or non-fatal stroke (HR 
0.84 [95% CI 0.76–0.93]; p < 0.0001) [34]. For the first 
time, an overall risk reduction for HHF (HR 0.91 [95% 
CI 0.83–0.99]; p = 0.0028) was shown. Overall, also all-
cause mortality (HR 0.88 [95% CI 0.83–0.95]; p = 0.001) 
was reduced significantly. In terms of renal risk reduc-
tion, the risk for the renal outcome of composite kidney 
outcome including macroalbuminuria (HR 0.83 [95% CI 
0.78–0.89]; p < 0.0001) was significantly reduced. Lira-
glutide, semaglutide, and dulaglutide and their respec-
tive studies seem to be the three major driving agents 
within the overall composite renal outcome including 
macroalbuminuria in the corresponding meta-analysis 
[34]. When looked at in more detail in respective trials, 
the composite renal outcome was to a large extent driven 
by a reduction of the risk of new onset of persistent mac-
roalbuminuria [15, 17, 19].
Results and observations from CVOTs have strongly 
impacted relevant guidelines—already in 2018, the ADA/
EASD consensus recommendation incorporated latest 
data from CVOTs and redefined the treatment algorithm 
with metformin as first line pharmaceutical therapy, fol-
lowed by second line pharmaceutical treatment accord-
ing to present comorbidities such as ASCVD, HF, or 
CKD [40]. Recently, the updated 2019 ESC Guidelines 
on diabetes, pre-diabetes, and cardiovascular diseases 
developed in collaboration with the EASD went a step 
further and incorporated GLP-1 RAs and/or SGLT-2is as 
first line pharmaceutical therapy in drug-naïve patients 
with ASCVD, or high/very high CV risk (target organ 
damage or multiple risk factors) [39].
Primary care in diabetes management
It was acknowledged that GLP-1 RAs and SGLT-2is 
become more relevant to a broader population, also 
including increasing application in primary care. While 
most CVOTs have included a large population of patients 
at high CV or renal risk which may more frequently pre-
sent to a specialist physician rather than a primary care 
physician, two of the published CVOTs have included 
large primary prevention cohorts: DECLARE-TIMI 58 
[11] and REWIND [19]. DECLARE-TIMI 58 investi-
gated the effect of dapagliflozin in a trial population of 
which 59.5% (10,186 patients) had no established CVD 
and demonstrated a 16% risk reduction of 3P-MACE 
(non-significant) in the multiple risk factors population 
[11]. In terms of primary prevention of kidney disease, 
results of SGLT-2 inhibitor CVOTs are backed up by the 
real-world data of CVD-REAL 3 [41]. The study investi-
gated renal and CV outcomes of SGLT-2is in a total of 
71,122 treatment initiation episodes from 65,231 indi-
vidual subjects in 5 different countries (Israel, U.K., Italy, 
Taiwan, and Japan), compared to other glucose-lowering 
drugs. The majority of treatment initiation episodes (ca. 
52%) were in patients with preserved kidney function 
(eGFR > 90 ml/min/1.73 m2) and ca. 38% of treatment ini-
tiation episodes in patients with an eGFR of 60 to < 90 ml/
min/1.73 m2, thus making the study relevant to primary 
care [41]. Overall, CVD-REAL 3 demonstrated signifi-
cantly less renal events in the SGLT-2i treatment group 
across the spectrum of assessed renal outcomes (e.g. 
composite of 50% eGFR decline or ESKD (HR 0.49 [95% 
CI 0.35–0.67]; p < 0.0001), or ESKD alone (HR 0.33 [95% 
CI 0.16–0.68]; p = 0.0024), with consistent results across 
pre-specified subgroups, like concomitant use of ACEis 
or ARBs. HHF (HR 0.60 [95% CI 0.47–0.76]; p < 0.0001) 
and all-cause mortality (HR 0.55 [95% CI 0.48–0.64]; 
p < 0.0001) were decreased compared to other glucose-
lowering drugs [41].
REWIND investigated the effect of dulaglutide in a 
population in which 68.5% (6793 patients) had not estab-
lished CVD [19], and reported a 13% risk reduction of 
3P-MACE (non-significant) in the multiple risk fac-
tors population [11, 19]. A recent exploratory analysis 
[42] of REWIND reported a significantly reduced risk of 
non-fatal stroke (HR 0.76 [95% CI 0.61–0.95]; p = 0.017) 
and ischaemic stroke (HR 0.75 [95% CI 0.59–0.94); 
p = 0.0115), and no significant effects on fatal stroke, 
haemorrhagic stroke, or stroke of unknown type when 
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comparing dulaglutide to placebo [42]. When analysing 
this in context of primary prevention, a significant effect 
was only observed for participants with previous CVD, 
however, a non-significant risk reduction of 20% (HR 0.80 
[95% CI 0.61–1.06]) was observed in primary prevention 
[42]. Even though more studies are needed on the poten-
tial benefits of GLP-1 RAs and SGLT-2is in a primary 
prevention population [43, 44], this is a first step towards 
making CVOTs, their outcomes and medications tested 
relevant for both broad primary and secondary preven-
tion populations, and thus both, specialist and primary 
care physicians.
Conclusion
The 5th CVOT Summit discussed key results of recently 
completed and published CVOTs in T2DM (CARO-
LINA, PIONEER-6, and REWIND) as well as two trials 
designed to evaluate specifically renal outcomes (CRE-
DENCE) and HF outcomes (DAPA-HF) in an interac-
tive, multi-disciplinary format. The summit considered 
latest data on possible mechanistic backgrounds, as well 
as potential and limitations of the recently published 
CVOTs and their implications in current guidelines for 
specialist and primary care provided to individuals with 
DM. In-depth discussions and presentations of upcoming 
CVOTs, renal and HF trials like DAPA-CKD, EMPA-Kid-
ney, VERTIS-CV, Emperor-Reduced, and Emperor-Pre-
served will be resumed at the 6th CVOT Summit, which 
will be held in Munich from 29 to 30 October 2020 (https 
://www.cvot.org).
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